SELLAS Life Sciences Group, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
8.00
|
|
Average Rating
|
4.75
|
|
# Strong Buys
|
3
|
|
# Buys
|
1
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.39
|
-0.34
|
0.05
|
12.82%
|
|
2022-06-30
|
-0.35
|
-0.41
|
-0.06
|
-17.14%
|
|
2022-03-31
|
-0.38
|
-1.05
|
-0.67
|
-176.32%
|
|
2021-12-31
|
-0.41
|
-0.42
|
-0.01
|
-2.44%
|
|
2021-09-30
|
-0.38
|
-0.45
|
-0.07
|
-18.42%
|
|
2021-06-30
|
-0.39
|
-0.30
|
0.09
|
23.08%
|
|
2021-03-31
|
-0.27
|
-0.16
|
0.11
|
40.74%
|
|
2020-12-31
|
-0.28
|
-0.28
|
0.00
|
0.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.80
|
|
2021-12-31
|
-1.33
|
|
2020-12-31
|
-2.13
|
|
2019-12-31
|
-21.72
|
|
2018-12-31
|
-182.50
|
|
2017-12-31
|
-204.60
|
|
2016-12-31
|
-68.70
|
|
2015-12-31
|
-77.80
|
|
2014-12-31
|
-5701.25
|
|
2013-12-31
|
-23700.00
|
|
2012-12-31
|
-19710.00
|
|
2011-12-31
|
-27272.40
|
|
2009-12-31
|
-37346.95
|
|
2008-12-31
|
-38100.00
|